Found: 24
Select item for more details and to access through your institution.
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 464, doi. 10.1111/apt.16712
- By:
- Publication type:
- Article
Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 3, p. 302, doi. 10.1111/apt.16619
- By:
- Publication type:
- Article
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 4, p. 186, doi. 10.1159/000519123
- By:
- Publication type:
- Article
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy.
- Published in:
- Microorganisms, 2020, v. 8, n. 11, p. 1792, doi. 10.3390/microorganisms8111792
- By:
- Publication type:
- Article
The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature.
- Published in:
- Gastroenterology Research & Practice, 2012, p. 1, doi. 10.1155/2012/916428
- By:
- Publication type:
- Article
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
- Published in:
- Digestive Diseases & Sciences, 2023, v. 68, n. 6, p. 2624, doi. 10.1007/s10620-022-07794-0
- By:
- Publication type:
- Article
Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 1, p. 90, doi. 10.1002/cpt.2601
- By:
- Publication type:
- Article
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1209, doi. 10.1111/apt.15735
- By:
- Publication type:
- Article
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 10, p. 1068, doi. 10.1111/apt.15514
- By:
- Publication type:
- Article
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
- Published in:
- Journal of Crohn's & Colitis, 2024, v. 18, n. 10, p. 1596, doi. 10.1093/ecco-jcc/jjae060
- By:
- Publication type:
- Article
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
- Published in:
- Journal of Crohn's & Colitis, 2024, v. 18, n. 8, p. 1270, doi. 10.1093/ecco-jcc/jjae038
- By:
- Publication type:
- Article
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
- Published in:
- Journal of Crohn's & Colitis, 2023, v. 17, n. 11, p. 1761, doi. 10.1093/ecco-jcc/jjad104
- By:
- Publication type:
- Article
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
- Published in:
- Journal of Crohn's & Colitis, 2023, v. 17, n. 7, p. 1066, doi. 10.1093/ecco-jcc/jjad020
- By:
- Publication type:
- Article
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
- Published in:
- Journal of Crohn's & Colitis, 2023, v. 17, n. 3, p. 338, doi. 10.1093/ecco-jcc/jjac141
- By:
- Publication type:
- Article
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
- Published in:
- Journal of Crohn's & Colitis, 2021, v. 15, n. 11, p. 1852, doi. 10.1093/ecco-jcc/jjab065
- By:
- Publication type:
- Article
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
- Published in:
- Journal of Crohn's & Colitis, 2021, v. 15, n. 7, p. 1130, doi. 10.1093/ecco-jcc/jjaa249
- By:
- Publication type:
- Article
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 10, p. 4440, doi. 10.1007/s12325-023-02603-0
- By:
- Publication type:
- Article
Comment on: "Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases".
- Published in:
- 2020
- By:
- Publication type:
- Letter
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program.
- Published in:
- Therapeutic Advances in Gastroenterology, 2022, p. 1, doi. 10.1177/17562848221136331
- By:
- Publication type:
- Article
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.
- Published in:
- Therapeutic Advances in Gastroenterology, 2021, v. 14, p. 1, doi. 10.1177/17562848211054710
- By:
- Publication type:
- Article
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.
- Published in:
- Therapeutic Advances in Gastroenterology, 2021, v. 14, p. 1, doi. 10.1177/17562848211005708
- By:
- Publication type:
- Article
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.
- Published in:
- Therapeutic Advances in Gastroenterology, 2021, v. 14, p. 1, doi. 10.1177/17562848211054710
- By:
- Publication type:
- Article
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.
- Published in:
- Therapeutic Advances in Gastroenterology, 2021, v. 14, p. 1, doi. 10.1177/17562848211005708
- By:
- Publication type:
- Article
The Role of CARD15 Mutations and Smoking in the Course of Crohn's Disease in a Mediterranean Area.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2008, v. 103, n. 3, p. 649, doi. 10.1111/j.1572-0241.2007.01589.x
- By:
- Publication type:
- Article